SCHEMBL1858970

SCHEMBL1858970

CS(=O)(=O)c1ccc(C(CC2CC(=O)C2)C(=O)Cl)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GCK P35557 8/20 0.55
KCNH2 Q12809 3/20 0.49
TRPV4 Q9HBA0 2/20 0.33
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
ADRA1D P25100 1/20 0.32
TBXA2R P21731 1/20 0.32
PTGDR Q13258 1/20 0.32
P2RX7 Q99572 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1858972 1.00 GCK (0.55) GCKKCNH2TRPV4SLC6A2SLC6A4
SCHEMBL1858826 0.91 GCK (0.66) GCKKCNH2TRPV4SLC6A2SLC6A4
SCHEMBL1858822 0.91 GCK (0.66) GCKKCNH2TRPV4SLC6A2SLC6A4
SCHEMBL1864199 0.91 GCK (0.55) GCKKCNH2TRPV4SLC6A2SLC6A4
SCHEMBL1864201 0.91 GCK (0.55) GCKKCNH2TRPV4SLC6A2SLC6A4
SCHEMBL1445384 0.87 KCNH2 (0.63) GCKKCNH2SLC6A3TBXA2RPTGDR
SCHEMBL1445381 0.87 KCNH2 (0.63) GCKKCNH2SLC6A3TBXA2RPTGDR
SCHEMBL21820635 0.82 GCK (0.66) GCKKCNH2TBXA2RPTGDR
SCHEMBL2642209 0.82 GCK (0.66) GCKKCNH2TBXA2RPTGDR
SCHEMBL1862618 0.82 GCK (0.66) GCKKCNH2TBXA2RPTGDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935699-B2 Pyrazole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2011-05-03 US disclosed
EP-2261216-A2 Pyrazoles as glucokinase activators F. Hoffmann-La Roche AG (CH) 2010-12-15 EP disclosed
CN-101541756-A Pyrazoles as glucokinase activators HOFFMANN LA ROCHE (CH) 2009-09-23 CN disclosed
EP-2046755-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. Hoffmann-Roche AG (CH) 2009-04-15 EP disclosed
WO-2008012227-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-31 WO disclosed
US-20080021032-A1 Pyrazole glucokinase activators BERTHEL STEVEN JOSEPH 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021032-A1 Pyrazole glucokinase activators GCKR, GCK, GALK1 GCK 2/4885KCNH2 2241/4885TRPV4 3850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.